--- title: The New RSV Drug Keeps Babies Out of the Hospital description: Beyfortus is effective at protecting infants from severe RSV, but it’s in short supply. canonical: https://time.com/6550598/rsv-drug-babies-beyfortus/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2023-12-27T22:00:00.000Z article:modified_time: 2026-02-24T16:53:28.663Z article:section: Health og:title: The New RSV Drug Keeps Babies Out of the Hospital og:description: Beyfortus is effective at protecting infants from severe RSV, but it’s in short supply. og:url: https://time.com/6550598/rsv-drug-babies-beyfortus/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt1894e39960edc980/698a437809208f10f241b0eb/GettyImages-166275571.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2121 og:image:height: 1193 og:image:alt: Female doctor injecting baby, close-up og:type: article twitter:card: summary_large_image twitter:title: The New RSV Drug Keeps Babies Out of the Hospital twitter:description: Beyfortus is effective at protecting infants from severe RSV, but it’s in short supply. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt1894e39960edc980/698a437809208f10f241b0eb/GettyImages-166275571.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # The New RSV Drug Keeps Babies Out of the Hospital > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=55bd7559-7ba1-48e5-bbf2-dad62f82cdd6&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | Subscribers | Open rate | | --- | --- | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | 540,000 | 45.6% | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | 430,000 | 50.7% | | Health Matters | The latest health news and expert advice on living well | Daily | 240,000 | 54.1% | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | 40,000 | 31.7% | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | 85,000 | 37.0% | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | 40,000 | 34.2% | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | 25,000 | 28.6% | Source: TIME, August 2026. Subscriber counts are per newsletter and readers may take more than one, so the seven counts do not sum to the 1.1 million+ unique newsletter audience. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Highest open rate | 54.1%, Health Matters | TIME, August 2026 | | Largest list | 540,000, The Brief | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=55bd7559-7ba1-48e5-bbf2-dad62f82cdd6&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=55bd7559-7ba1-48e5-bbf2-dad62f82cdd6&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Dec 27, 2023 10:00 PM UTC  Nirsevimab is effective in protecting infants from severe RSV, but it’s in short supply. Nirsevimab is effective in protecting infants from severe RSV, but it’s in short supply. Sarah Monte—Getty Images/Westend61  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Dec 27, 2023 10:00 PM UTC Doctors and parents celebrated the major advances that came in 2023 to treat respiratory syncytial virus (RSV), which sends up to 80,000 children under age five to the hospital each year in the U.S. This year, the U.S. Food and Drug Administration approved two critical ways to reduce the risk of RSV in young kids: a [vaccine](https://time.com/6306970/emabrgoed-fda-approves-first-rsv-vaccine-for-pregnant-women/) for pregnant mothers that can protect newborns, and a drug [treatment](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers) for babies under one year. In a study published in the _New England Journal of Medicine_, researchers report encouraging real-world data that show how effective the drug treatment, nirsevimab (brand name: Beyfortus), can be. The study, which was funded by the drug's makers Sanofi and AstraZeneca, included more than 8,000 infants in France, Germany, and the U.K. who were one year old or younger and entering their first RSV season, which runs from fall to spring. Nivrsevimab is a monoclonal antibody that acts almost like a vaccine, training a child's immune system to recognize RSV and defend against it. Half of the babies in the study were randomly assigned to receive nirsevimab, and half received no treatment. The drug was 83% effective in preventing hospitalization among those getting it, and 75% effective in reducing severe RSV. These results were similar regardless of the baby’s age, gestational age, or sex. "From a scientific point of view, it's fantastic that were able to prevent more than 80% of children who received the drug from going to the hospital," says Dr. Saul Faust, pediatrician at University Hospital Southampton and co-leader of the study. The findings support [recommendations](https://www.cdc.gov/vaccines/vpd/rsv/hcp/child.html) by the U.S. Centers for Disease Control and Prevention (CDC) that any baby under 8 months old receive a single injection of nirsevimab before their first RSV season if the mother has not already been vaccinated against RSV. But since the drug was approved in July, its makers, AstraZeneca and Sanofi, have not been able to keep up with the [surge in demand](https://time.com/6330543/rsv-treatment-shortage/). “The demand for Beyfortus has far surpassed any previous standard,” an AstraZeneca spokesperson said in response to questions about ongoing issues with supply. In October, the CDC [alerted](https://emergency.cdc.gov/han/2023/han00499.asp) doctors about ways to restrict supply of nirsevimab to babies at highest risk of RSV complications, such as younger and lower weight babies, and those born with underlying health conditions. The agency also recommended that some of these high-risk babies, including those born prematurely and who have heart and lung conditions, continue to receive an older, existing RSV treatment called palivizumab (brand name: Synagis). That can keep supplies of nirsevimab available for babies who don’t qualify for palivizumab. While paliviziumab is safe and effective, it requires monthly injections throughout RSV season, so doctors and parents were hoping to start taking advantage of nirsevimab's single-injection. For families with babies who aren't at especially high risk of RSV complications, Dr. Rick Malley, a pediatrician at Harvard Medical School and Boston Children's Hospital, says there are ways to protect infants even if they can't get the shot. Especially during the holidays, Malley says parents can ask visitors to avoid exposing themselves to the baby if they have any symptoms of respiratory infections, such as a fever, cough, or runny nose. If visitors insist on getting close to the baby, touching the infant's feet rather than face can also reduce the risk of passing on any infections. The other reassuring news is that in general, RSV infections tend to peak earlier in the season, so it's possible the highest risk is over for this year. Still, nirsevimab's manufacturer anticipates that supplies will gradually continue to increase in coming months. “Approximately 230,000 additional doses will be made available in mid-January for this RSV season,” says the AstraZeneca spokesperson. “This follows the announcement in November that 77,000 additional doses were being made available.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6550598/rsv-drug-babies-beyfortus/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6550598/rsv-drug-babies-beyfortus/"},"headline":"The New RSV Drug Keeps Babies Out of the Hospital","datePublished":"2023-12-27T22:00:00.000Z","dateModified":"2026-02-24T16:53:28.663Z","description":"Beyfortus is effective at protecting infants from severe RSV, but it’s in short supply.","url":"https://time.com/6550598/rsv-drug-babies-beyfortus/","keywords":["Drugs","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt1894e39960edc980/698a437809208f10f241b0eb/GettyImages-166275571.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt1894e39960edc980/698a437809208f10f241b0eb/GettyImages-166275571.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Female doctor injecting baby, close-up","caption":"Female doctor injecting baby, close-up","creditText":"Sarah Monte—Getty Images/Westend61","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/drugs/","name":"Drugs"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6550598/rsv-drug-babies-beyfortus/","name":"The New RSV Drug Keeps Babies Out of the Hospital"}}]}] ```